The independent source for health policy research, polling, and news.
41 - 60 of 697 Results
A bill designed to force PBMs to pay higher fees to independent drugstores sailed through the state House, but lobbyists are marshaling their forces to kill the measure in the Senate.
It’s the Trump administration vs. the federal courts, as the Department of Government Efficiency continues to try to cancel federal contracts and programs and fire workers. But in the haste to cut things, jobs and programs are being eliminated even if they align with the new administration’s goal to “Make America Healthy Again.” Jessie Hellmann of CQ Roll Call, Sarah Karlin-Smith of the Pink Sheet, and Rachel Roubein of The Washington Post join KFF Health News’ Julie Rovner to discuss these stories and more.
At least 20 states have settled disputes with health insurance giant Centene since 2021 over allegations that its pharmacy benefit manager operation overcharged their Medicaid programs. Two holdouts appear to remain: Georgia has not yet settled, and Florida officials won’t answer questions about its Centene situation.
Frustrated by high health care prices, many who backed President Donald Trump support strong government actions to protect patients. It’s unclear whether GOP leaders will listen.
Frustrated by spiraling drug costs, California lawmakers want to increase oversight of pharmaceutical industry intermediaries known as pharmacy benefit managers. It’s unclear whether they can persuade Gov. Gavin Newsom to get on board.
“An Arm and a Leg” is collecting stories for a new series about how Americans get the medicine they need when faced with sticker shock.
From rolling back drug pricing policies to limiting gender-affirming care, President Donald Trump signed several health-related executive orders in the first hours of his second presidency. Here’s a roundup of the changes and what they mean.
With just days to go before the official launch of a new administration, the GOP-led Congress is putting together plans on how to enact incoming President Donald Trump’s agenda, with a particular emphasis on cutting spending on the Medicaid program. Meanwhile, the Biden administration makes major moves in its last days, including banning a controversial food dye and ordering cigarette companies to minimize their nicotine content. Joanne Kenen of Johns Hopkins University and Politico Magazine, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the latest KFF Health News “Bill of the Month” feature, about a colonoscopy that came with a much larger price tag than estimated.
As Gov. Gavin Newsom enters the second half of his final term, health care stands out as his most ambitious but glaringly incomplete initiative for California residents. The issue will likely shape his national profile for better or worse. And now, Donald Trump brings a new wrinkle.
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” PBMs — or force them to change.
KFF Health News gives readers a chance to comment on a recent batch of stories.
Florida sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Now, nearly a year after the FDA gave the state the green light, the program has yet to begin.
Listen to KFF Health News' Jackie Fortiér recount how a backyard snakebite led to a harrowing hospitalization — and big bills — for a San Diego family.
Health care has ebbed and surged as an election issue throughout the presidential campaign. Here are the ways some of the most consequential changes in health policies could hinge on whether Vice President Kamala Harris or former President Donald Trump wins.
Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative reform attempts. Georgia Republican Gov. Brian Kemp, though, vetoed a related bill that would have helped independent pharmacies, citing the unfunded cost of the move.
Every year, Medicare officials encourage beneficiaries to shop around for their drug coverage. Few take the time. This year, it might be more important than ever.
As part of her presidential campaign, Vice President Kamala Harris has rolled out a plan for Medicare to provide in-home long-term care services. The proposal would fill a longtime need for families trying to simultaneously care for young children and older parents, but its enormous price tag makes it a promise unlikely to be fulfilled. Meanwhile, a growing number of Republican candidates up and down the ballot facing voter backlash over their support for abortion restrictions are trying to reinvent their positions. Shefali Luthra of The 19th, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, excerpts from a KFF lunch with “Shark Tank” panelist and generic drug discounter Mark Cuban, who has been consulting with the Harris campaign about health care issues.
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
The 2024 presidential race is taking on a familiar tone — with Democrats accusing Republicans of wanting to ban abortion and repeal the Affordable Care Act and Republicans insisting they have no such plans. Voters will determine whom they believe. Meanwhile, for the second time in a month, a state judge overturned an abortion ban, but few expect the decision to settle the matter. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Anna Edney of Bloomberg News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Lauren Sausser, who reported and wrote the latest KFF Health News-Washington Post “Bill of the Month,” about a teenage athlete whose needed surgery lacked a billing code.
© 2026 KFF